Two large-scale pharmacogenomic studies were published recently in this journal. Genomic
data are well correlated between studies; however, the measured drug response data are
highly discordant. Although the source of inconsistencies remains uncertain, it has potential
implications for using these outcome measures to assess gene–drug associations or select
potential anticancer drugs on the basis of their reported results.